• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Opiate substitution treatment associated with reduced risk of HIV transmission among injection drug users

bys25qthea
October 22, 2012
in Chronic Disease, Infectious Disease, Neurology, Psychiatry, Public Health
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD

Key findings:

  1. This meta-analysis found a 54% reduction in risk of HIV infection associated with opiate substitution treatment among injection drug users.
  2. HIV incidence was reported to be higher in methadone detoxification treatment when compared to placebo or methadone maintenance therapy.

Primer: HIV prevention and disease control are priorities in public health. Rates of HIV infection amongst injection drug users are alarmingly high due to the efficiency of transmission through sharing of injecting equipment. Opiate substitution treatment aims to reduce risk of transmission by prescribing a drug with similar effects as the drug of use but with reduced associated risk. Currently, the most common form of substitution therapy is methadone syrup taken orally. Burphrenine has recently become more widely used in the form of an oral tablet. Alternatives to substitution therapy include detoxification or residential rehabilitation. Substitution treatment has been associated with reductions in behaviors that carry a high-risk of HIV transmission and could potentially improve adherence to antiretroviral therapy in patients already diagnosed with HIV. An earlier systematic review found that treatment is consistently associated with reduced illicit opioid use, injection drug use, sharing of injecting equipment, and multiple sex partners, but this review could not quantify the risk reduction due to methodological limitations.

Background reading:

  1. Gowing LR. The role of opioid substitution treatment in reducing HIV transmission. BMJ 2012;345:e6425.
  2. Gowing L, Farrell MF, Bornemann R, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.:CD004145. DOI:10.1002/14651858.CD004145.pub4.

This [systematic review] study: This systematic review and meta-analysis sought to determine the effect of opiate substitution therapy on HIV transmission among injection drug users. The review included data from 15 observational studies, of which 12 were published and 3 were unpublished. Methadone maintenance treatment was generally associated with lower risk of HIV infection. Data from 9 studies which could be appropriately pooled in a meta-analysis quantified this effect as a 54% reduction in risk of HIV infection (rate ratio 0.46, 95% CI 0.32-0.67; P<0.001) with significant heterogeneity between studies. Univariable meta-regression analysis found no evidence that the effectiveness of methadone maintenance treatment varied by geographical region, site of recruitment, or provision of incentives to participants. As a secondary objective, the review identified four studies comparing methadone detoxification treatment with either no treatment or with methadone maintenance treatment and HIV incidence was reported to be higher in those undergoing detoxification.

In sum: This study provides the first quantitative estimate of the association between opiate substitution therapy and HIV incidence. These results strengthen and support findings of a previous review by identifying additional relevant studies. This was achieved by including studies that were not yet published and studies where effects of opiate substitution treatment were reported with secondary analyses and therefore may not have had relevant terms in the title or abstract. The study had a number of limitations. A key limitation is that results were based on data from observational studies, which are prone to bias; a randomized controlled trial, however, is no longer ethical given the large beneficial effect observed with opiate substitution treatment. Results may overestimate or underestimate true effects if, for example, more motivated individuals tend to enter treatment or infrequent/lower-risk injection drug users were not included. The control of confounders was inconsistent between studies and the effect of co-interventions, such as supervised injection facilities, is unclear. The generalisability of the results is also limited since studies on treatments other than methadone maintenance did not meet eligibility criteria. Further investigation is necessary to determine the safety and effectiveness of non-methadone substitution treatments. Greater attention should also be directed at reducing risk of HIV transmission through sexual behavior.

RELATED REPORTS

Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results

 Click to read in BMJ

Written by [AdC] and [AC]

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. DISCLAIMER: Posts are not medical advice and are not intended as such. Please see a healthcare professional if you seek medical advice.

Previous Post

Prophylactic probiotic use trends toward decreased incidence of nosocomial infections in preterm infants

Next Post

HPV vaccination not associated with increase in sexual activity-related outcomes amongst 11 and 12 year-old females

RelatedReports

An illustration showing human lungs, a tray with sampling devices, and a teal awareness ribbon, representing lung cancer diagnostics and lymph node sampling.
2MM Trial Briefs

Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results

October 26, 2026
Illustration showing the lungs with a tumor, a vial representing medication, and surgical tools, indicating lung cancer treatment involving toripalimab.
2MM Trial Briefs

Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results

October 25, 2026
An illustration of the pancreas, highlighting cancer cells related to pancreatic cancer and molecular structures, indicating targeted research in oncology.
2MM Trial Briefs

Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial

October 25, 2026
An older woman looks thoughtfully to the side, with dumbbells, running shoes, and a bottle of supplements nearby, suggesting themes of exercise and health in geriatrics.
Chronic Disease

An electronic health record tool for exercise prescription may reduce fall rate among older adults

October 24, 2026
Next Post

HPV vaccination not associated with increase in sexual activity-related outcomes amongst 11 and 12 year-old females

Multivitamin use decreases total cancer risk among older men

Autologous chondrocyte implantation can restore normal knee function in younger patients with full-thickness cartilage lesions

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer, Amgen reports in interim phase 3 results
  • Sacituzumab tirumotecan improved overall survival versus platinum chemotherapy in company-reported final phase 3 results
  • Camupepimut did not improve disease-free survival versus observation in pancreatic cancer in the randomized phase 2 AMPLIFY-7P trial
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.